IP Verse

Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer

Patent No. EP3266456 (titled "Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer") was filed by Ipsen Biopharm on Jun 12, 2013. The application was issued on May 5, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKFeb 4, 2022ELKINGTON AND FIFE
TEVA PHARMACEUTICALSFeb 2, 2022D YOUNG
SANDOZFeb 1, 2022KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3266456

IPSEN BIOPHARM
Application Number
EP17169098A
Filing Date
Jun 12, 2013
Status
Granted And Under Opposition
Apr 3, 2021
Publication Date
May 5, 2021
External Links
Slate, Register , Google Patents